• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Nano-micelle Drug Delivery System for the Treatment of Brain Tumors

Research Project

Project/Area Number 16591432
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Cerebral neurosurgery
Research InstitutionThe University of Tokyo

Principal Investigator

INO Yasushi  The University of Tokyo, Faculty of Medicine, Project Assistant Professor, 医学部附属病院, 研究拠点形成特任教員 (50372371)

Co-Investigator(Kenkyū-buntansha) TODO Tomoki  The University of Tokyo, Faculty of Medicine, Lecturer, 医学部附属病院, 講師 (80272566)
KATAOKA Kazunori  The University of Tokyo, the Graduate School of Engineering, Professor, 大学院・工学系研究科, 教授 (00130245)
NISHIYAMA Nobuhiro  The University of Tokyo, Faculty of Medicine, Research Associate, 医学部附属病院, 助手 (10372385)
Project Period (FY) 2004 – 2005
Project Status Completed (Fiscal Year 2005)
Budget Amount *help
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2005: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2004: ¥1,800,000 (Direct Cost: ¥1,800,000)
KeywordsCancer / Central Nervous System / Drug Delivery / nano material / biomedical material / 悪性脳腫瘍 / 化学療法 / ドラッグ・デリバリー・システム / ナノミセル
Research Abstract

The use of polymeric micelles is one of the promising modalities of macromolecular carrier systems. Dichloro (1,2-diaminocyclohexane)platinum(II) (DACHPt) is a second-generation platinum based anticancer drug which is highly hydrophobic and is toxic when administered systemically. We have developed a polymeric micelle incorporating DACHPt (DACHPt/m) via the polymer-metal complex formation between DACHPt and poly(ethylene glycol)-poly(glutamic acid) block copolymers [PEG-P(Glc)]. In vivo antitumor effect of DACHPt/m was tested in Neuro2a (murine neuroblastoma) subcutaneous and intracerebral tumor models. Oxaliplatin, a less toxic derivative of DACHPt, was also used as a control. The maximum tolerated dose (MTD) of DACHPt/m in A/J mice was 1.75mg/kg and similar to that of oxaliplatin when administered from the tail vein three times every other day. Nonetheless, DACHPt/m was more effective in inhibiting the Neuro2a subcutaneous tumor growth than oxaliplatin at theed MTD level. Dach-Pt/m was also effective in the Neuro2a intracerebral tumor model and prolonged the survival of tumor-baring mice compared with oxaliplatin. Accumulation of DACHPt/m was 9.5 and 1.7 times higher in subcutaneous and intracerebral tumors, respectively, than that of oxaliplatin 48 hours after drug administration. These results suggest that the polymeric micelle system can be a useful macromolecular drug carrier for the treatment of brain tumors.

Report

(3 results)
  • 2005 Annual Research Report   Final Research Report Summary
  • 2004 Annual Research Report
  • Research Products

    (8 results)

All 2006 2005

All Journal Article (8 results)

  • [Journal Article] Triple combination of oncolytic HSV-1 vectors "armed" with interleukin 12, interleukin 18 or soluble B7-1 results in enhanced antitumor efficacy2006

    • Author(s)
      Ino Y, Saeki Y, Fukuhara H, Todo T
    • Journal Title

      Clin Cancer Res 12・2

      Pages: 643-652

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Annual Research Report 2005 Final Research Report Summary
  • [Journal Article] Triple combination of oncolytic HSV-1 vectors "armed" with interleukin 12, interleukin 18 or soluble B7-1 results in enhanced antitumor efficacy.2006

    • Author(s)
      Ino Y, Saeki Y, Fukuhara H, Todo T
    • Journal Title

      Clin Cancer Res 12(2)

      Pages: 643-652

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] High-dose conformal radiotherapy for supratentorial malignant glioma2005

    • Author(s)
      Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T
    • Journal Title

      Lancet Oncology 6・12

      Pages: 953-960

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Annual Research Report 2005 Final Research Report Summary
  • [Journal Article] Triple gene-deleted oncolytic herpes simplex virus vector double-armed with IL-18 and soluble B7-1 constructed by BAC-mediated system.2005

    • Author(s)
      Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T
    • Journal Title

      Cancer Res 65・23

      Pages: 10663-10668

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Annual Research Report 2005 Final Research Report Summary
  • [Journal Article] Oncolytic herpes simplex virus vector G47 Δ in combination with androgen ablation for treatment of human prostate adenocorcinoma2005

    • Author(s)
      Fukuhara H, Martuza RL, Robkin SD, Ito Y, Todo T.
    • Journal Title

      Clin Cancer Res 11・21

      Pages: 7886-7890

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] High-dose conformal radiotherapy for supratentorial malignant glioma2005

    • Author(s)
      Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T
    • Journal Title

      Lancet Oncology 6(12)

      Pages: 953-960

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Oncolytic herpes simplex virus vector G 47Δ in combination with androgen ablation for the treatment of human prostate adenocarcinoma.2005

    • Author(s)
      Fukuhara H, Martuza RL, Rabkin SD, I to Y, Todo T
    • Journal Title

      Clin Cancer Res 11(21)

      Pages: 7886-7890

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Triple gene-deleted oncolytic herpes simplex virus vector double-armed with IL-18 and soluble B7-1 constructed by BAC-mediated system.2005

    • Author(s)
      Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T
    • Journal Title

      Cancer Res 65(23)

      Pages: 10663-10668

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary

URL: 

Published: 2004-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi